{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:28:17Z","timestamp":1786771697969,"version":"build-2736575974"},"reference-count":45,"publisher":"The Fukushima Society of Medical Science","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2026]]},"DOI":"10.5387\/fms.26-00021","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T22:10:44Z","timestamp":1786572644000},"source":"Crossref","is-referenced-by-count":0,"title":["Pathophysiological and clinical significance of hepatokine Fetuin-A and myocardial N-myristoylation in heart failure"],"prefix":"10.5387","author":[{"given":"Yusuke","family":"Tomita","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Misaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Yokokawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuchika","family":"Takeishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tsutsui H, Isobe M, Ito H, <i>et al.<\/i> JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure \u2014 digest version \u2014. Circ J, <b>83<\/b>(10): 2084-2184, 2019.","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling : mechanisms : part 1 of 2. Circulation, <b>128<\/b>(4): 388-400, 2013.","DOI":"10.1161\/CIRCULATIONAHA.113.001878"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol, <b>15<\/b>(7): 387-407, 2018.","DOI":"10.1038\/s41569-018-0007-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Suzuki S, Takeishi Y. Molecular mechanisms and clinical features of heart failure. Fukushima J Med Sci, <b>64<\/b>(3): 116-124, 2018.","DOI":"10.5387\/fms.2018-17"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Takeishi Y, Walsh RA. Cardiac hypertrophy and failure : lessons learned from genetically engineered mice. Acta Physiol Scand, <b>173<\/b>(1): 103-111, 2001.","DOI":"10.1046\/j.1365-201X.2001.00890.x"},{"key":"6","unstructured":"6. Ndumele CE, Rangaswami J, Chow SL, <i>et al.<\/i> Cardiovascular-kidney-metabolic health : A presidential advisory from the American heart association. Circulation, <b>148<\/b>(20): 1606-1635, 2023."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shouman WA, Najmeddine S, Sinno L, <i>et al.<\/i> Hepatokines and their role in cardiohepatic interactions in heart failure. Eur J Pharmacol, <b>992<\/b>(177356): 177356, 2025.","DOI":"10.1016\/j.ejphar.2025.177356"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Capone F, Vacca A, Bidault G, <i>et al.<\/i> Decoding the liver-heart axis in cardiometabolic diseases. Circ Res, <b>136<\/b>(11): 1335-1362, 2025.","DOI":"10.1161\/CIRCRESAHA.125.325492"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cao Y, Wang Y, Zhou Z, <i>et al.<\/i> Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure. Science, <b>377<\/b>(6613): 1399-1406, 2022.","DOI":"10.1126\/science.abn0910"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sato Y, Yoshihisa A, Takeishi Y. Organ injury and its management in heart failure : Liver, kidney, and thyroid gland dysfunction. Fukushima J Med Sci, <b>70<\/b>(3): 111-117, 2024.","DOI":"10.5387\/fms.24-00002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fert-Bober J, Murray CI, Parker SJ, <i>et al.<\/i> Precision profiling of the cardiovascular post-translationally modified proteome : Where there is a will, there is a way. Circ Res, <b>122<\/b>(9): 1221-1237, 2018.","DOI":"10.1161\/CIRCRESAHA.118.310966"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Conibear AC. Deciphering protein post-translational modifications using chemical biology tools. Nat Rev Chem, <b>4<\/b>(12): 674-695, 2020.","DOI":"10.1038\/s41570-020-00223-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Watt MJ, Miotto PM, De Nardo W, <i>et al.<\/i> The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev, <b>40<\/b>(5): 1367-1393, 2019.","DOI":"10.1210\/er.2019-00034"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Trepanowski JF, Mey J, Varady KA. Fetuin-A : a novel link between obesity and related complications. Int J Obes (Lond), <b>39<\/b>(5): 734-741, 2015.","DOI":"10.1038\/ijo.2014.203"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Dautova Y, Kozlova D, Skepper JN, <i>et al.<\/i> Fetuin-A and albumin alter cytotoxic effects of calcium phosphate nanoparticles on human vascular smooth muscle cells. PLoS One, <b>9<\/b>(5): e97565, 2014.","DOI":"10.1371\/journal.pone.0097565"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Smith ER, Hanssen E, McMahon LP, <i>et al.<\/i> Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS One, <b>8<\/b>(4): e60904, 2013.","DOI":"10.1371\/journal.pone.0060904"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pal D, Dasgupta S, Kundu R, <i>et al.<\/i> Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med, <b>18<\/b>(8): 1279-1285, 2012.","DOI":"10.1038\/nm.2851"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yoshihisa A, Ishibashi S, Matsuda M, <i>et al.<\/i> Clinical implications of hepatic hemodynamic evaluation by abdominal ultrasonographic imaging in patients with heart failure. J Am Heart Assoc, <b>9<\/b>(15): e016689, 2020.","DOI":"10.1161\/JAHA.120.016689"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tomita Y, Misaka T, Yoshihisa A, <i>et al.<\/i> Decreases in hepatokine Fetuin-A levels are associated with hepatic hypoperfusion and predict cardiac outcomes in patients with heart failure. Clin Res Cardiol, <b>111<\/b>(10): 1104-1112, 2022.","DOI":"10.1007\/s00392-022-02023-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sato Y, Yoshihisa A, Kanno Y, <i>et al.<\/i> Liver stiffness assessed by Fibrosis-4 index predicts mortality in patients with heart failure. Open Heart, <b>4<\/b>(1): e000598, 2017.","DOI":"10.1136\/openhrt-2017-000598"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Sugawara Y, Yoshihisa A, Ishibashi S, <i>et al.<\/i> Liver congestion assessed by hepatic vein waveforms in patients with heart failure. CJC Open, <b>3<\/b>(6): 778-786, 2021.","DOI":"10.1016\/j.cjco.2021.02.004"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Forman DE, Fleg JL, Kitzman DW, <i>et al.<\/i> 6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. J Am Coll Cardiol, <b>60<\/b>(25): 2653-2661, 2012.","DOI":"10.1016\/j.jacc.2012.08.1010"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sato T, Yoshihisa A, Kanno Y, <i>et al.<\/i> Cardiopulmonary exercise testing as prognostic indicators : Comparisons among heart failure patients with reduced, mid-range and preserved ejection fraction. Eur J Prev Cardiol, <b>24<\/b>(18): 1979-1987, 2017.","DOI":"10.1177\/2047487317739079"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tomita Y, Misaka T, Sugawara Y, <i>et al.<\/i> Reduced fetuin-A levels are associated with exercise intolerance and predict the risk of adverse outcomes in patients with heart failure : The role of cardiac-hepatic-peripheral interaction. J Am Heart Assoc, <b>13<\/b>(17): e035139, 2024.","DOI":"10.1161\/JAHA.124.035139"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Rudloff S, Janot M, Rodriguez S, <i>et al.<\/i> Fetuin-A is a HIF target that safeguards tissue integrity during hypoxic stress. Nat Commun, <b>12<\/b>(1): 549, 2021.","DOI":"10.1038\/s41467-020-20832-7"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Blumenthal JB, Gitterman A, Ryan AS, <i>et al.<\/i> Effects of Exercise Training and Weight Loss on Plasma Fetuin-A Levels and Insulin Sensitivity in Overweight Older Men. J Diabetes Res, 2017: 1492581, 2017.","DOI":"10.1155\/2017\/1492581"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Misu H, Takamura T, Takayama H, <i>et al.<\/i> A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab, <b>12<\/b>(5): 483-495, 2010.","DOI":"10.1016\/j.cmet.2010.09.015"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Takeishi R, Misaka T, Ichijo Y, <i>et al.<\/i> Increases in hepatokine selenoprotein P levels are associated with hepatic hypoperfusion and predict adverse prognosis in patients with heart failure. J Am Heart Assoc, <b>11<\/b>(11): e024901, 2022.","DOI":"10.1161\/JAHA.121.024901"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Chou R-H, Huang P-H, Hsu C-Y, <i>et al.<\/i> Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci Rep, <b>6<\/b>(1): 33953, 2016.","DOI":"10.1038\/srep33953"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sato T, Yamauchi H, Suzuki S, <i>et al.<\/i> Serum cholinesterase is an important prognostic factor in chronic heart failure. Heart Vessels, <b>30<\/b>(2): 204-210, 2015.","DOI":"10.1007\/s00380-014-0469-8"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ix JH, Shlipak MG, Brandenburg VM, <i>et al.<\/i> Association between human fetuin-A and the metabolic syndrome : data from the Heart and Soul Study. Circulation, <b>113<\/b>(14): 1760-1767, 2006.","DOI":"10.1161\/CIRCULATIONAHA.105.588723"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Weikert C, Stefan N, Schulze MB, <i>et al.<\/i> Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation, <b>118<\/b>(24): 2555-2562, 2008.","DOI":"10.1161\/CIRCULATIONAHA.108.814418"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ketteler M, Bongartz P, Westenfeld R, <i>et al.<\/i> Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis : a cross-sectional study. Lancet, <b>361<\/b>(9360): 827-833, 2003.","DOI":"10.1016\/S0140-6736(03)12710-9"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Laughlin GA, Cummins KM, Wassel CL, <i>et al.<\/i> The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults : the Rancho Bernardo study. J Am Coll Cardiol, <b>59<\/b>(19): 1688-1696, 2012.","DOI":"10.1016\/j.jacc.2012.01.038"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Miura S, Misaka T, Sekine T, <i>et al.<\/i> Detyrosinated \u03b1-tubulin mediates mitochondrial dysfunction and diastolic impairment in heart failure with preserved ejection fraction. FEBS Lett, <b>599<\/b>(17): 2474-2490, 2025.","DOI":"10.1002\/1873-3468.70119"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Dian C, P\u00e9rez-Dorado I, Rivi\u00e8re F, <i>et al.<\/i> High-resolution snapshots of human N-myristoyltransferase in action illuminate a mechanism promoting N-terminal Lys and Gly myristoylation. Nat Commun, <b>11<\/b>(1): 1132, 2020.","DOI":"10.1038\/s41467-020-14847-3"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Timms RT, Zhang Z, Rhee DY, <i>et al.<\/i> A glycine-specific N-degron pathway mediates the quality control of protein N-myristoylation. Science, <b>365<\/b>(6448): eaaw4912, 2019.","DOI":"10.1126\/science.aaw4912"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Wang B, Dai T, Sun W, <i>et al.<\/i> Protein N-myristoylation : functions and mechanisms in control of innate immunity. Cell Mol Immunol, <b>18<\/b>(4): 878-888, 2021.","DOI":"10.1038\/s41423-021-00663-2"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Torn\u00f8e CW, Christensen C, Meldal M. Peptidotriazoles on solid phase : [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J Org Chem, <b>67<\/b>(9): 3057-3064, 2002.","DOI":"10.1021\/jo011148j"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Rostovtsev VV, Green LG, Fokin VV, <i>et al.<\/i> A stepwise huisgen cycloaddition process : copper(I)-catalyzed regioselective \u201cligation\u201d of azides and terminal alkynes. Angew Chem Int Ed Engl, <b>41<\/b>(14): 2596-2599, 2002.","DOI":"10.1002\/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Tomita Y, Anzai F, Misaka T, <i>et al.<\/i> Targeting N-myristoylation through NMT2 prevents cardiac hypertrophy and heart failure. JACC Basic Transl Sci, <b>8<\/b>(10): 1263-1282, 2023.","DOI":"10.1016\/j.jacbts.2023.06.006"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Mendell JR, Al-Zaidy S, Shell R, <i>et al.<\/i> Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, <b>377<\/b>(18): 1713-1722, 2017.","DOI":"10.1056\/NEJMoa1706198"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Greenberg B, Taylor M, Adler E, <i>et al.<\/i> Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease. N Engl J Med, <b>392<\/b>(10): 972-983, 2025.","DOI":"10.1056\/NEJMoa2412392"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Suzuki S, Takeishi Y, Niizeki T, <i>et al.<\/i> Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J, <b>155<\/b>(1): 75-81, 2008.","DOI":"10.1016\/j.ahj.2007.08.013"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Takeishi Y, Niizeki T, Arimoto T, <i>et al.<\/i> Serum resistin is associated with high risk in patients with congestive heart failure A novel link between metabolic signals and heart failure. Circ J, <b>71<\/b>(4): 460-464, 2007.","DOI":"10.1253\/circj.71.460"}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/advpub\/0\/advpub_26-00021\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:05:29Z","timestamp":1786770329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/advpub\/0\/advpub_26-00021\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":45,"URL":"https:\/\/doi.org\/10.5387\/fms.26-00021","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"26-00021"}}